InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023
May 04, 2023 at 06:30 am EDT
Share
InfuSystem Holdings, Inc. reaffirmed earnings guidance for the full year 2023. For the period, the company expected net revenue growth estimated to be in the range of 8% to 10%, or approximately $118 million to $121 million in net revenues.
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segmentâs core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.
INFUSYSTEM HOLDINGS, INC. 
